COMPASS PATHWAYS PLC (CMPS) Profit Breakdown
- 2026-06-30: Single Operating -$253.79M.
- 2025-06-30: Single Operating -$38.40M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2019-12-31 to 2026-06-30
- Data captured
Profit by product
Net Income (Loss) Attributable to Parent: each quarter (3 month)
| Quarter end | Single Operating |
|---|---|
| 2026-06-30 | -$253.79M |
| 2025-06-30 | -$38.40M |
Operating income: each quarter (3 month)
| Quarter end | Single Operating |
|---|---|
| 2026-06-30 | -$52.37M |
| 2025-06-30 | -$42.93M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |